Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
CagriSema is an injection given once a week, into the skin of the abdomen, thigh, or upper arm
731 patients took part in the study, and were followed up to 104 weeks
Remarkably, TRIUMPH-1 Phase 3 results revealed an average weight loss of 28.3% over 80 weeks, making it a promising option compared to current GLP-1 agonists like Wegovy and new dual-agonists like Tirzepatide
By activating both GIP and GLP-1 receptors simultaneously, it addresses the hormonal roots of weight gain rather than just its symptoms, making it a particularly promising option for women whose bodies have stopped responding to conventional approaches
Clinical Guidelines and Research Evidence Leading medical organizations, such as KDIGO (Kidney Disease: Improving Global Outcomes) and the American Diabetes Association, endorse GLP-1 receptor agonists for individuals with type 2 diabetes and CKD
US$ 20.80
US$ 23.89
US$ 29.53
US$ 27.33
US$ 24.84
US$ 25.04
US$ 28.29
US$ 25.02
US$ 21.21
